Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation

Journal of Dermatological Science

Volumn 76, Issue 2, 2014, Pages 96-103

  Hemmerle, Teresa ^a   Zgraggen, Silvana ^a   Matasci, Mattia ^b   Halin, Cornelia ^a   Detmar, Michael ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

Author keywords

Antibody cytokine fusion protein; Chronic skin inflammation; Fibronectin; Interleukin 4; Psoriasis

Indexed keywords

ETANERCEPT; FIBRONECTIN; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F8; RECOMBINANT INTERLEUKIN 4; RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE MODEL; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; SKIN BLOOD VESSEL; TREATMENT OUTCOME;

EID: 84908054079     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.07.012     Document Type: Article

References (45)

1. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-870.
2. Johnson-Huang L.M., Lowes M.A., Krueger J.G. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 2012, 5:423-430.
3. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-500.
4. Gisondi P., Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007, 6:515-520.
5. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013, 168:412-420.
6. Krueger J.G., Fretzin S., Suarez-Farinas M., Haslett P.A., Phipps K.M., Cameron G.S., et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012, 130:145-150. e149.
7. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102:2075-2080.
8. Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., van Eden W., et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003, 9:40-50.
9. Duan H., Koga T., Kohda F., Hara H., Urabe K., Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001, 26:119-120.
10. Tepper R.I. The eosinophil-mediated antitumor activity of interleukin-4. J Allergy Clin Immunol 1994, 94:1225-1231.
11. Tepper R.I., Pattengale P.K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989, 57:503-510.
12. Wei M.X., Tamiya T., Hurford R.K., Boviatsis E.J., Tepper R.I., Chiocca E.A. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 1995, 6:437-440.
13. Yu J.S., Wei M.X., Chiocca E.A., Martuza R.L., Tepper R.I. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993, 53:3125-3128.
14. Kurtz D.M., Tschetter L.K., Allred J.B., Geyer S.M., Kurtin P.J., Putnam W.D., et al. Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leuk Lymphoma 2007, 48:1290-1298.
15. Whitehead R.P., Lew D., Flanigan R.C., Weiss G.R., Roy V., Glode M.L., et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother 2002, 25:352-360.
16. Whitehead R.P., Unger J.M., Goodwin J.W., Walker M.J., Thompson J.A., Flaherty L.E., et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 1998, 21:440-450.
17. Wong H.L., Costa G.L., Lotze M.T., Wahl S.M. Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med 1993, 177:775-780.
18. Biedermann T., Mailhammer R., Mai A., Sander C., Ogilvie A., Brombacher F., et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol 2001, 31:1582-1591.
19. Li J., Li X., Zhang Y., Zhou X.K., Yang H.S., Chen X.C., et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med 2010, 12:481-490.
20. Ren X., Li J., Zhou X., Luo X., Huang N., Wang Y., et al. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 2009, 219:232-240.
21. Pasche N., Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012, 17:583-590.
22. Kontermann R.E. Antibody-cytokine fusion proteins 2012, Arch Biochem Biophys.
23. Doll F., Schwager K., Hemmerle T., Neri D. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther 2013, 15:R138.
24. Schwager K., Bootz F., Imesch P., Kaspar M., Trachsel E., Neri D. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod 2011, 26:2344-2352.
25. Schwager K., Kaspar M., Bootz F., Marcolongo R., Paresce E., Neri D., et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009, 11:R142.
26. Trachsel E., Bootz F., Silacci M., Kaspar M., Kosmehl H., Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007, 9:R9.
27. Trachsel E., Kaspar M., Bootz F., Detmar M., Neri D. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol 2007, 127:881-890.
28. Galeazzi M., Baldi C., Prisco E., Bardelli M., Neri D., Giovannoni L., et al. A phase Ib clinical trial with F8-IL10, an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis (RA), used in combination with methotrexate (MTX). Arthritis Rheum 2012, 64(Suppl. 10):1291.
29. Rybak J.N., Roesli C., Kaspar M., Villa A., Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007, 67:10948-10957.
30. Schliemann C., Wiedmer A., Pedretti M., Szczepanowski M., Klapper W., Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009, 33:1718-1722.
31. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008, 122:2405-2413.
32. Hemmerle T., Neri D. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 2013, 134:467-477.
33. Pasche N., Wulhfard S., Pretto F., Carugati E., Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with Paclitaxel. Clin Cancer Res 2012, 18:4092-4103.
34. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
35. Detmar M., Brown L.F., Schon M.P., Elicker B.M., Velasco P., Richard L., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998, 111:1-6.
36. Kunstfeld R., Hirakawa S., Hong Y.K., Schacht V., Lange-Asschenfeldt B., Velasco P., et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004, 104:1048-1057.
37. Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003, 102:161-170.
38. Schwager K., Hemmerle T., Aebischer D., Neri D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 2013, 133:751-760.
39. Frey K., Schliemann C., Schwager K., Giavazzi R., Johannsen M., Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol 2010, 184:2540-2548.
40. Borsi L., Balza E., Bestagno M., Castellani P., Carnemolla B., Biro A., et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102:75-80.
41. Janeway C. Immunobiology: the immune system in health and disease 2005, Garland Science, New York. 6th ed.
42. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbaugh C., Tepper R.I., et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998, 188:1039-1046.
43. Hemmerle T., Doll F., Neri D. The antibody-based delivery of IL4 to the neo-vasculature cures mice with arthritis. Proc Natl Acad Sci USA 2014, 111:12008-12012.
44. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004, 50:1412-1419.
45. Silacci M., Baenziger-Tobler N., Batay S., Leibig W., Bertschinger-Ehler J., Grabulovski D. COVA301. A highly potent bispecific inhibitor of IL-17A and TNFα. mAbs 2012, 4(1):14-20.